MONTE ROSA THERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 9Avg age 56Avg tenure 4.6y
MW
Markus Warmuth
Chief Executive Officer
Age 55Since 2019-12-31Profile →
+13
Executives5
Board of directors9
MW
Markus Warmuth→
Director/Board Member
Age 55Since 2019-12-31
AB
Ali Behbahani→
Director/Board Member
Age 50Since 2020-03-31
KB
Kimberly Blackwell→
Director/Board Member
Age 57Since 2020-05-31
CS
Christine Siu→
Director/Board Member
Age 49Since 2020-11-30
CL
Chandra Paul Leo→
Director/Board Member
Age 55Since 2020-08-31
AS
Andrew Schiff→
Chairman
Age 60Since 2023-05-31
JS
Jan Skvarka→
Chairman
Age 59Since 2022-02-28
AM
Anthony Manning→
Director/Board Member
Age 64Since 2023-07-24
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| T. Rowe Price International Ltd. | 7.955 % | 6,720,188 |
| NEA Management Co. LLC | 7.922 % | 6,692,298 |
| Dimension Management LP | 6.704 % | 5,663,265 |
| BlackRock Advisors LLC | 6.249 % | 5,279,112 |
| TCG Crossover Management LLC | 5.471 % | 4,622,151 |
Catalog · 2026-07-09
Registry officers14
| Name | Role | Since | Shares |
|---|---|---|---|
| Andrew Schiff | Chairman | 2023-05-31 | - |
| Filip Janku | Chief Tech/Sci/R&D Officer | 2021-05-31 | - |
| Jan Skvarka | Chairman | 2022-02-28 | - |
| Jennifer Champoux | Chief Operating Officer | 2021-02-28 | - |
| John Castle | Chief Tech/Sci/R&D Officer | — | - |
| Magnus Walter | Chief Tech/Sci/R&D Officer | 2026-03-16 | - |
| Markus Warmuth | Chief Executive Officer | 2019-12-31 | - |
| Ali Behbahani | Director/Board Member | 2020-03-31 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus strong buyMean target 26.88Range 19–37Analysts 8
19Mean 26.8837
- Strong buy 2
- Buy 8
Broker actions40
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | 25 | 2026-10-05 |
| HC Wainwright & Co. | Initiated | Buy | 25 | 2026-10-01 |
| Wedbush | Reiterated | Outperform | 27 | 2026-09-09 |
| Guggenheim | Reiterated | Buy | 28 | 2026-08-25 |
| JP Morgan | Maintained | Overweight | 27 | 2026-08-07 |
| Guggenheim | Maintained | Buy | 28 | 2026-08-07 |
| Wells Fargo | Maintained | Overweight | 27 | 2026-08-07 |
| Wedbush | Maintained | Outperform | 27 | 2026-08-03 |
| Guggenheim | Maintained | Buy | 35 | 2026-06-30 |
| JP Morgan | Maintained | Overweight | 31 | 2026-05-11 |
| Guggenheim | Maintained | Buy | 30 | 2026-03-18 |
| Wells Fargo | Maintained | Overweight | 29 | 2026-03-18 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.